Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.
Director Of Translate Bio Sold $78.09 Million In Stock
Jean-Francois Formela, Director at Translate Bio (NASDAQ:TBIO), made a large insider sell on September 14, according to a new SEC filing.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Sanofi’s $1.9 Billion Bet On Kadmon: What You Need to Know
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another
Translate Bio Granted Patent ‘MRNA therapy for Pompe disease’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6595&f=G&l=50&d=PTXT&p=132&S1=20210817&OS=20210817&RS=20210817
Inside Sanofi’s $3.2B Translate Bio Buyout
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ:TBIO) earlier this month, Sanofi SA (NASDAQ:SNY) expressed interest in selling off around…
Translate Bio Q2 Sales $72.65M Up From $16.32M YoY
Translate Bio (NASDAQ:TBIO) reported $72.65 million in sales this quarter. This is a 345.18 percent increase over sales of $16.32 million the same period last year.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Roth Capital Maintains Neutral on Translate Bio, Lowers Price Target to $38
Roth Capital analyst Tony Butler maintains Translate Bio (NASDAQ:TBIO) with a Neutral and lowers the price target from $45 to $38.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)